ALKERMES | ALKS - Zinsaufwendungen Für Schuld





Zinsaufwendungen Für Schuld Veränderung Datum
AbbVie USD 645M 69M 2026-03
Acadia Pharmaceuticals USD 0 4.12M 2024-09
ALKERMES USD 20.89M 8.62M 2026-03
Amgen USD 657M 4M 2026-03
Biogen USD 72.6M 12.6M 2025-06
BioMarin Pharmaceutical USD 14.96M 12.18M 2026-03
Bristol-Myers Squibb USD 411M 21M 2026-03
Coherus Biosciences USD 2.25M 76K 2025-12
Eli Lilly USD 114.7M 134.3M 2025-09
Gilead Sciences USD 240M 15M 2026-03
Heron Therapeutics USD 600K 100K 2024-12
Ionis Pharmaceuticals USD 17M 1000K 2026-03
J&J USD 43M 25M 2026-03
Merck USD 479M 67M 2026-03
Minerva Neurosciences USD 2.31M 60K 2024-06
Nektar Therapeutics USD 9.77M 3.75M 2025-12
Neurocrine Biosciences USD 1.1M 0 2024-03
Otsuka Holdings JPY 2.21B 866M 2025-12
Ovoca Bio EUR 7K 6K 2022-06
Pfizer USD 671M 40M 2026-03
Regeneron Pharmaceuticals USD 12.9M 700K 2026-03
Vertex Pharmaceuticals USD 3.3M 0 2025-12